Defence Therapeutics Inc. (FRA:DTC)

Germany flag Germany · Delayed Price · Currency is EUR
0.5020
-0.0400 (-7.38%)
At close: Dec 4, 2025
31.76%
Market Cap 31.73M
Revenue (ttm) n/a
Net Income (ttm) -2.21M
Shares Out n/a
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 5,658
Open 0.4980
Previous Close 0.5420
Day's Range 0.4980 - 0.5020
52-Week Range 0.3170 - 1.1700
Beta n/a
RSI 50.62
Earnings Date Nov 19, 2025

About Defence Therapeutics

Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; the anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; the ARM-X ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2017
Country Canada
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol DTC
Full Company Profile

Financial Performance

Financial numbers in CAD Financial Statements

News

There is no news available yet.